Ignite Creation Date:
2024-05-06 @ 3:08 PM
Last Modification Date:
2024-10-26 @ 1:43 PM
Study NCT ID:
NCT04531163
Status:
UNKNOWN
Last Update Posted:
2020-08-28
First Post:
2020-08-21
Brief Title:
Possible Ameliorating Effect of N- Acetylcysteine NAC on Type-II Diabetes Induced Nephropathy
Sponsor:
Al-Azhar University
Organization:
Al-Azhar University
Study Overview
Official Title:
Possible Ameliorating Effect of N- Acetylcysteine on Type-II Diabetes Induced Nephropathy
Status:
UNKNOWN
Status Verified Date:
2020-08
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NAC
Brief Summary:
The study is focused on the possible improving effect of N-acetylcysteine on nephropathy of type-2 diabetic patients
Study design Prospective clinical based study The aim of this work is to study the effect of N-acetylcysteine NAC on proteinuria and on the serum level of lipoprotein a LPa in diabetes induced nephropathy in type-2 diabetic patients
Study design Prospective clinical based study The aim of this work is to study the effect of N-acetylcysteine NAC on proteinuria and on the serum level of lipoprotein a LPa in diabetes induced nephropathy in type-2 diabetic patients
Detailed Description:
This study will be carried on 60 participants with Type 2 Diabetes with age over 20 years
Participants will be classified into two groups
1 Group I Interventional treated with NAC dose of 1200 mgday for two months in conjunction with conventional treatment
2 Group II Non-interventional control group receive conventional treatment
All patients will undergo the following
1 Full medical history will be taken
2 Laboratory investigations as follows
Blood samples will be collected for analysis after overnight fasting at the beginning and after 2 months of the study for determination of
1 Total cholesterol T-chol
2 Plasma triglycerides TG
3 High density lipoprotein cholesterol HDL-C
4 Low density lipoprotein cholesterol LDL-C
5 Fasting blood sugar
6 Blood urea nitrogen BUN
7 Serum creatinine SCr
8 Urine analysis
9 Glycated hemoglobin HbA1c
10 Lipoprotein a In addition blood pressure will be measured for 24 hr
Participants will be classified into two groups
1 Group I Interventional treated with NAC dose of 1200 mgday for two months in conjunction with conventional treatment
2 Group II Non-interventional control group receive conventional treatment
All patients will undergo the following
1 Full medical history will be taken
2 Laboratory investigations as follows
Blood samples will be collected for analysis after overnight fasting at the beginning and after 2 months of the study for determination of
1 Total cholesterol T-chol
2 Plasma triglycerides TG
3 High density lipoprotein cholesterol HDL-C
4 Low density lipoprotein cholesterol LDL-C
5 Fasting blood sugar
6 Blood urea nitrogen BUN
7 Serum creatinine SCr
8 Urine analysis
9 Glycated hemoglobin HbA1c
10 Lipoprotein a In addition blood pressure will be measured for 24 hr
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None